NEW YORK, June 30, 2020 /PRNewswire-PRWeb/ -- The
Conference Forum is presenting the 5th annual IO Combinations 360°
Summit on October 1-2, 2020
virtually. Leaders in the IO Community representing biotech,
pharma, academia, cancer research organizations, regulatory and
investments convene to present the latest data and advancements for
IO Combinations.
"What makes the 5th annual IO Combinations 360° extraordinary is
the leadership from across science, clinical and business
communities, coming together to share cutting-edge data and
advancements driving the field," said Kate
Woda, Director, IO Combinations 360°.
Immunobiology pioneer Dr Ronald
Germain, Chief, Laboratory of Immune System Biology and
Director, Center for Advanced Tissue Imaging, National Institute of
Allergy and Infectious Diseases at the NCI will deliver the opening
keynote, providing a detailed cellular and functional analysis of
the tumor microenvironment in the context of immunotherapy using
highly multiplexed imaging and machine learning.
The financial keynote is delivered by expert analyst,
Edward Tenthoff, Managing Director,
Senior Biotech Analyst, Piper
Sandler & Co, where he will provide an evaluation and
forecast of the IO combination landscape.
The 2020 guest keynote is cancer veteran Steve Hamilton, who will share his clinical
trial journey with an IO vaccine involving the MAGE-A3 protein
paired with IL-2.
Dr Omid Hamid, The Angeles Clinic
and Research Institute, Dr Alexandra
Snyder, Merck Research Labs, Dr James Gulley, National Cancer Institute and Dr
Raluca Verona, Janssen are
co-chairing. Other distinguished speakers including:
- Jose Baselga, MD, PhD,
AstraZeneca
- Raphaël F Rousseau, MD, PhD, Gritstone Oncology
- Alexandra Snyder, MD, Merck
Research Labs
- Kristen Hege, MD, BMS
- Stephen Baylin, MD, Johns Hopkins University
- Eytan Ruppin, MD, PhD, National
Cancer Institute
- Mary Antonysamy, PhD, GSK
- Christina Derluth, MD, Seattle Genetics
- Alex Franzusoff, PhD, PACT
Pharma
- Dmitriy Zamarin MD, PhD,
Memorial Sloan Kettering Cancer Center
- Saul Priceman, PhD, City of
Hope
- Mark O'Hara, MD, University of Pennsylvania
IO Combinations 360° is divided into the following seven plenary
discussions: Discovery and Preclinical Science, Translational
Science and Emerging Biomarkers, Clinical Operations and
Development, Next Generation Cell Therapy, Business Developments,
and Emerging Technologies.
"I look forward to discussing with and hearing from leaders in
the immunotherapy field regarding advancements ranging from cell
and gene therapy, IO biomarkers and science driven combinations, "
said Dr Theresa LaValle, VP,
Translational Medicine and Regulatory Affairs, Parker Institute of
Cancer Immunotherapy.
For full event details on IO Combinations 360°, click here.
About IO Combinations 360˚
IO Combinations 360˚ is a two-day conference focused on the
combinations used in immunotherapy to treat various forms of
cancer. IO Combinations 360° was born from the Conference Forum's
Immuno-Oncology 360° event as the need for a more focused program
on combinations became increasingly clear with the enormous
increase in overall investment.
About the Conference Forum
The Conference Forum is a life science industry research firm
that develops conferences primarily around how to get therapeutics
to patients faster. They examine and challenge the complex
ecosystem of drug development and delivery, bringing ideas together
from a variety of sources to help advance clinical research with
common goals that are patient-focused. They are committed to
creating the best content, exchange of ideas and solutions among
peers, as well as providing high quality networking.
SOURCE The Conference Forum